Glenmark Pharma USA Launches Lacosamide Injection

Glenmark Pharmaceuticals Inc., USA, a subsidiary of Glenmark Pharmaceuticals Ltd, has announced the launch of Lacosamide Injection USP, 200 mg/20 mL (10 mg/mL), Single-Dose Vials. This product is bioequivalent and therapeutically equivalent to UCB, Inc.'s Vimpat® Injection. The US market for Vimpat® Injection achieved approximately $15.2 million in annual sales for the 12 months ending April 2026. This launch is part of Glenmark's strategy to expand its differentiated product portfolio in the United States, aiming to enhance healthcare provider capabilities and improve patient access to affordable treatments.